Potential Cure for Type 1 Diabetes on the Horizon with Immune System Reprogramming
Researchers at the Medical University of South Carolina (MUSC) are pioneering a novel approach to treating and potentially curing type 1 diabetes (T1D). Led by Dr. Leonardo Ferreira, the team is leveraging a $1 million grant from Breakthrough T1D to develop a two-part cellular therapy that aims to restore insulin production without the need for lifelong immunosuppressant drugs.
Understanding Type 1 Diabetes
Type 1 diabetes is an autoimmune condition affecting approximately 1.5 million Americans, according to the Centers for Disease Control and Prevention . In T1D, the body’s immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. Without insulin, the body cannot regulate blood sugar levels, leading to potentially serious complications like nerve damage, blindness, coma, and even death .
A Novel Two-Part Cellular Therapy
The research team’s strategy focuses on addressing the two major challenges in T1D treatment: a shortage of functional beta cells and immune rejection of transplanted cells. To overcome the donor tissue limitations, the team is producing stem cell-derived islet cells in the laboratory.
The core of the innovation lies in Dr. Ferreira’s expertise in engineering the immune system. Regulatory T cells (Tregs) play a crucial role in controlling immune responses and preventing autoimmune attacks. The team modifies these Tregs using chimeric antigen receptors (CARs), essentially creating a “GPS signal” that directs them to specific surface proteins on the transplanted beta cells .
Once localized, these engineered Tregs act as targeted “bodyguards,” protecting the beta cells from immune system attack. This interaction functions like a lock and key, signaling the immune system to stand down and preserve insulin production.
Eliminating the Need for Immunosuppressants
A significant advantage of this combined cellular therapy is the potential to eliminate the need for immunosuppressive drugs. These drugs, although necessary after traditional transplants, carry substantial long-term risks, particularly for children. The lab-produced beta cells also offer a scalable and reliable supply, addressing the current shortage of donor tissue. Currently, a single transplant often requires cells from three or four donors, whereas the engineered beta cells can be manufactured, frozen, and stored without losing quality.
The Path Forward: Testing and Long-Term Impact
While promising, this therapy requires further research before clinical use. Researchers are currently investigating the durability of the protective effects, having observed benefits lasting up to one month in preclinical studies using humanized mice . The new funding will support efforts to extend this protection, improve delivery methods, and explore the potential of multiple doses for longer-lasting results.
“We’re trying to develop a therapy that would perform for all people with type 1 diabetes at every stage, even people who have had the disease for many years and have no beta cells left,” said Dr. Ferreira .
Beyond Diabetes: A Framework for Regenerative Medicine
This research extends beyond T1D, offering a potential framework for regenerative medicine and immune-based therapies. Dr. Ferreira believes this approach could fundamentally change how medicine is practiced, shifting from symptom management to replacing missing cells and ultimately understanding the root causes of autoimmune diseases.